Biopharmaceutical company Promomed has started supplying analogues of the anti-obesity drug Ozempik with the active ingredient semaglutide for the treatment of diabetes mellitus and correction of overweight to Uzbekistan. In the future, the company intends to significantly expand its presence by consistently including in its supply portfolio the latest drugs for the treatment of diabetes and obesity, as well as medicines for the treatment of oncological diseases.